Skip to main content
. 2018 Oct 10;18(6):5044–5052. doi: 10.3892/mmr.2018.9547

Figure 1.

Figure 1.

IL-10 promotes cell proliferation and leads to G2 phase activation in TDSCs. TDSCs were treated with the indicated concentrations of IL-10 for (A) 1, (B) 3 and (C) 5 days. Cell proliferation was subsequently assessed with a Cell Counting Kit-8 assay. (D) TDSCs were treated with 10 ng/ml IL-10 for 3 days and subjected to cell cycle analysis by flow cytometry. (E) The percentage of TDSCs in the G1 phase decreased, whereas the percentage in the G2/M phase increased. Data are expressed as the mean ± standard error of the mean. *P<0.05, **P<0.01 vs. control cells. IL-10, interleukin-10; TDSCs, tendon-derived stem cells; P, population.